United States Drug Manufacturers - General news

22:32 16 Jul 2026

Ad Hoc News Earnings Main company 🇺🇸 United States

Merck stock holds gains as Keytruda drives double digit revenue growth

Merck's stock reflects the company's strong performance, driven primarily by the oncology leader Keytruda, which has fueled double-digit revenue growth. In its latest quarter, total revenue reached $15 billion, with Keytruda sales alone hitting $6 billion, representing a 20% year-on-year increase. The company's vaccine …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

22:07 16 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan

Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences (NASDAQ: GILD), reported an open-market sale of 3,000 shares of common stock on July 15, 2026, at an average price of $129.9192 per share. This sale was conducted under a Rule 10b5-1 trading …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

22:02 16 Jul 2026

Investing.com Canada Earnings Main company 🇺🇸 United States

Gilead Sciences chief comm & corp aff officer sells $389,757 in stock

Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences (NASDAQ:GILD), sold 3,000 shares of company stock for approximately $389,757 on July 15, 2026, as part of a pre-arranged trading plan. Despite the sale, the stock is considered potentially undervalued according to InvestingPro …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

21:44 16 Jul 2026

Zacks Earnings Main company 🇺🇸 United States

Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?

Amgen (AMGN) is analyzed for its potential to surpass earnings estimates in its upcoming report, leveraging its strong historical performance and positive Zacks Earnings ESP. The company has consistently beaten estimates in the last two quarters, and its current Earnings ESP of +1.17% combined …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

21:40 16 Jul 2026

CryptoSlate Market update Main company 🇺🇸 United States

AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume

This article provides details on AstraZeneca Tokenized Stock (AZNX), a digital asset tracking AstraZeneca PLC's share price. It covers current price, market cap, trading volume, and market performance statistics. The article also explains AZNX's function as a tracker certificate within the xStocks ecosystem, offering …

AZN main company

Sharemaestro market context Price below Trend Line 52 weeks -1.4%

20:00 16 Jul 2026

The Globe and Mail Analyst action Main company 🇺🇸 United States

Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV)

Healthcare sector analysts have issued bullish sentiments on Fractyl Health, Inc. (GUTS) and AbbVie (ABBV). H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating for Fractyl Health with an $8.00 price target, while William Blair analyst Matt Phipps maintained a Buy rating for AbbVie. …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

19:47 16 Jul 2026

Investing.com Deals and strategy Main company 🇺🇸 United States

Freedom Capital upgrades Johnson & Johnson stock rating on strong quarter

Freedom Capital upgraded Johnson & Johnson (NYSE:JNJ) to Buy from Hold and raised its price target to $280 due to strong quarterly performance, particularly in TREMFYA, CAPLYTA, and SPRAVATO revenues. The firm is now more confident J&J will surpass its $100 billion revenue target …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

19:41 16 Jul 2026

Benzinga Earnings Main company 🇺🇸 United States

FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio

Merck & Co. (NYSE: MRK) has received FDA approval for LIPFENDRA (enlicitide), a new oral PCSK9 inhibitor for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). This once-daily pill significantly reduced LDL-C in Phase 3 trials, with some studies showing up to a 60% …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

19:09 16 Jul 2026

Simply Wall Street Deals and strategy Main company 🇺🇸 United States

Johnson & Johnson (JNJ) Crosses $100 Billion As DePuy Synthes Buys Spine Tech

Johnson & Johnson (JNJ) has reached an annual revenue of over $100 billion for the first time, supported by strong Q2 results and raised guidance for 2026. This milestone is coupled with MedTech unit DePuy Synthes acquiring Expanding Innovations to bolster JNJ's presence in …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

18:46 16 Jul 2026

Ad Hoc News Earnings Main company 🇺🇸 United States

AbbVie stock trades steadily as investors weigh Humira erosion and pipeline progress

AbbVie Inc. is navigating a transitional period marked by the decline of its flagship drug Humira due to biosimilar competition, balanced by the growth of its newer immunology and neuroscience treatments. Investors are focusing on the pace at which these new therapies can offset …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

18:10 16 Jul 2026

Pharmaceutical Technology Earnings Main company 🇺🇸 United States

Novo secures European approval for oral Wegovy to extend lead over Lilly

Novo Nordisk has received European approval for its oral weight-loss drug, Wegovy (semaglutide), strengthening its lead over competitors like Eli Lilly in the obesity treatment market. This approval follows similar decisions in the US and UK, making oral Wegovy the first and currently only …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

18:07 16 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?

AbbVie (ABBV) is set to report its second-quarter 2026 results, with investor attention on its neuroscience portfolio following a 26% revenue increase in Q1. The Zacks Consensus Estimate predicts 15% year-over-year growth for neuroscience revenues, driven by drugs like Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

17:42 16 Jul 2026

marketscreener.com Analyst action Main company 🇺🇸 United States

Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers

Illumina has announced that its Billion Cell Atlas alliance has expanded to include new members, such as Formation Bio, bringing in more AI-driven drug developers. This alliance, which also includes AstraZeneca, Merck, and Eli Lilly and Company, uses Illumina's extensive genome-wide perturbation data to …

LLY main company MRK main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

17:36 16 Jul 2026

MarketWatch Earnings Main company 🇺🇸 United States

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day

Bristol Myers Squibb Co. (BMY) stock advanced 3.05% to $60.51 on Thursday, outperforming the broader market which saw the S&P 500 Index fall 0.51% and the Dow Jones Industrial Average fall 0.20%. This marks the stock's second consecutive day of gains despite an overall …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

17:07 16 Jul 2026

GuruFocus Market update Main company 🇺🇸 United States

Amgen Inc (AMGN) Stock Up 3.7% but GF Value Says Overvalued -- G

Amgen Inc's stock rose 3.7% to $371.58, but GuruFocus's GF Value™ indicates it is 5.1% overvalued compared to its fair value of $353.68. Despite a strong GF Score™ of 81/100, driven by high profitability and growth, the company shows weaknesses in financial strength and …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

16:41 16 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Amarin (AMRN) COO Keenan details RSU vesting and ADS tax withholding

David Paul Keenan, EVP and Chief Operating Officer of Amarin Corporation (AMRN), reported recent equity compensation activities. This included the vesting of 3,688 Restricted Stock Units (RSUs) linked to American Depositary Shares (ADSs) and the withholding of 1,926 ADSs to cover tax obligations. Following …

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

16:36 16 Jul 2026

Quiver Quantitative Earnings Main company 🇺🇸 United States

Why AbbVie (ABBV) Stock Is Up Today

AbbVie (ABBV) stock rose 3.3% today, driven by positive Wall Street sentiment and anticipation of its second-quarter earnings report. Analyst price target increases and new regulatory submissions for drugs like RINVOQ and SKYRIZI indicate strong pipeline momentum, despite ongoing challenges with Humira. Investors are …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

16:35 16 Jul 2026

Bloomberg Law News Regulatory and legal Main company 🇺🇸 United States

Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer

Biogen Inc. has appointed Michael J. Parini as its new chief legal officer, effective August 3rd, where he will oversee the company's global legal and compliance functions and report to the CEO. Parini brings over two decades of experience in the biopharmaceutical industry, having …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

16:15 16 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement

Merck & Co Inc (MRK) stock rose by 3.24% on July 16, driven by optimism regarding its late-stage oncology pipeline, strategic advancements in its immunology portfolio, and diversification efforts. Analysts have increased price targets, citing strong performance in its vaccine and animal health segments. …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

16:15 16 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send?

AbbVie Inc.'s stock (ABBV) rose by 3.32% due to positive clinical trial outcomes for Skyrizi and Rinvoq, reinforcing its post-Humira growth strategy. Institutional investors are favoring healthcare stocks like AbbVie for its dividend profile and resilient cash flow, amidst a broader market shift from …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6%

16:11 16 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

GSK plc (NYSE: GSK) insiders add ADSs through dividend reinvestment

GSK plc reported that several senior leaders and non-executive directors acquired American Depositary Shares (ADS) between July 10 and July 14, 2026. These acquisitions were a result of the automatic reinvestment of cash dividends paid to shareholders on July 9, 2026, with ADS prices …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

15:44 16 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?

Pfizer's stock is trading below its 50-day and 200-day simple moving averages, indicating investor caution due to declining COVID-related revenues and upcoming patent expirations. Despite these challenges and a dull 2026 financial outlook, the company is rebuilding its pipeline in oncology and obesity through …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

15:40 16 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

Amarin (NASDAQ: AMRN) CLO gets RSU shares; some withheld for tax

Jonathan Provoost, EVP and Chief Legal Officer of Amarin Corporation, reported RSU activity where he acquired 3,688 American Depositary Shares (ADS) and had 1,264 ADS withheld for tax obligations, which is not considered a market sale. This activity relates to a 7,376-unit RSU grant …

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

15:11 16 Jul 2026

Investing.com Nigeria Earnings Main company 🇺🇸 United States

Grifols doses first patients in two phase 3 immunoglobulin trials By Investing.com

Grifols has announced the dosing of the first patients in two Phase 3 clinical trials for its immunoglobulin therapeutics, GAMUNEX-C and XEMBIFY. These trials aim to expand the U.S. labels for these treatments, with one focusing on secondary immunodeficiency in blood cancer patients and …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

15:08 16 Jul 2026

The Motley Fool Earnings Main company 🇺🇸 United States

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?

This article compares Johnson & Johnson and Eli Lilly and Company, two major pharmaceutical giants, as potential investments in 2026. While Johnson & Johnson offers stability and diversification across medical technology and pharmaceuticals, Eli Lilly presents a high-growth opportunity driven by its dominant position …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

14:38 16 Jul 2026

Trefis Earnings Main company 🇺🇸 United States

The Real Engine Behind Johnson & Johnson Stock’s Next Climb

Johnson & Johnson (JNJ) stock has paused after a significant run-up, leading investors to question its next growth driver. The article suggests that while one segment faces a slowdown, the Innovative Medicine division, excluding the impact of STELARA, achieved double-digit growth. This strong performance, …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

14:08 16 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences (GILD) has garnered investor attention, with its stock performing well recently. The article discusses factors influencing its future performance, including revisions to earnings estimates, projected revenue growth, past financial results, and valuation metrics. Zacks currently rates Gilead as a Zacks Rank #3 …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

13:40 16 Jul 2026

MassDevice Deals and strategy Main company 🇺🇸 United States

J&J’s DePuy Synthes acquires spine implant maker Expanding Innovations

Johnson & Johnson's DePuy Synthes has acquired Expanding Innovations, a company specializing in expandable implant technology for spine surgery, to strengthen its spine portfolio and expand its presence in the expandable interbody cage segment. Expanding Innovations' proprietary non-screw-based interbody cage technology is designed to …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

13:38 16 Jul 2026

Psychedelic Alpha Deals and strategy Main company 🇺🇸 United States

Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion

Eli Lilly has acquired AtaiBeckley, a developer of psychedelic therapies, for up to $3.8 billion. The deal includes an upfront payment of $2.8 billion and up to an additional $1 billion in milestone-based payments for AtaiBeckley's lead candidates, intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

13:25 16 Jul 2026

Ad Hoc News Earnings Main company 🇺🇸 United States

Merck stock steadies as investors track its drug pipeline

Merck & Co. (MRK) stock is currently steady, with investors focusing on its drug pipeline and upcoming earnings given its status as a prominent U.S. pharmaceutical company. The company's business revolves around prescription medicines, particularly in oncology and vaccines, making late-stage development crucial for …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

13:17 16 Jul 2026

BioSpace Earnings Main company 🇺🇸 United States

J&J sees Spravato sales surge as psychedelic competitors loom

Johnson & Johnson's depression drug Spravato saw a 40% Q2 revenue increase, reaching $584 million, marking it as a key franchise with potential peak sales of $5 billion. While psychedelic treatments like Compass Pathways' COMP360 and Definium Therapeutics' DT120 show promising clinical results and …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

13:08 16 Jul 2026

WSJ Deals and strategy Main company 🇺🇸 United States

Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion

Eli Lilly has announced an agreement to acquire AtaiBeckley, a mental-health-focused pharmaceutical company, for an initial sum of $2.8 billion. This deal, part of Eli Lilly's recent acquisition trend, involves paying $6.75 per share in cash, representing a 26% premium over AtaiBeckley's previous closing …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

12:43 16 Jul 2026

Stock Titan Market update Main company 🇺🇸 United States

Grifols Trial Could Expand Treatment Options for 60,000 Patients

Grifols has initiated two new Phase 3 trials, SIGMA and XPERT, to expand the U.S. indications for its flagship immunoglobulins, GAMUNEX-C and XEMBIFY. The SIGMA trial focuses on preventing infections in hematologic cancer patients with secondary immunodeficiency, while XPERT aims to demonstrate XEMBIFY's non-inferiority …

GRFS main company

Sharemaestro market context Price below Trend Line 52 weeks -23.4%

12:35 16 Jul 2026

The Manila Times Regulatory and legal Main company 🇺🇸 United States

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma, along with its licensee Genevant, has filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. The company also announced it received approximately $178 million from Moderna as part of a settlement …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

12:26 16 Jul 2026

Seeking Alpha Regulatory and legal Main company 🇺🇸 United States

Merck cholesterol drug, Lipfendra, approved by FDA (MRK:NYSE)

Merck's oral PCSK9 inhibitor, Lipfendra (enlicitide), has received FDA approval for adults with high cholesterol levels. The drug aims to reduce low-density lipoprotein cholesterol, commonly known as bad cholesterol. This approval provides a new treatment option for managing high cholesterol.

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

12:09 16 Jul 2026

PR Newswire Deals and strategy Main company 🇺🇸 United States

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

Eli Lilly and Company is set to acquire AtaiBeckley, a clinical-stage biopharmaceutical company focused on developing therapies for mental health conditions, including treatment-resistant depression. The acquisition will expand Lilly's neuroscience pipeline, with AtaiBeckley's lead asset, BPL-003, already having U.S. FDA Breakthrough Therapy Designation and …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%